Department of Epidemiology, School of Medicine, Jinan University, Guangzhou.
Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Department of Rare and Head and Neck Oncology, Zhejiang Cancer Hospital; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou.
Eur J Cancer Prev. 2024 Jan 1;33(1):62-68. doi: 10.1097/CEJ.0000000000000830. Epub 2023 Jul 19.
While timely assessment of long-term survival in thyroid cancer patients is critical for assessing early detection and screening programs for thyroid cancer, those data are sorely lacking in China. We aimed to timely and accurately assess the long-term survival of thyroid cancer patients in eastern China.
Patients diagnosed with thyroid cancer during 2004-2018 from four cancer registries in Taizhou, eastern China were included. The 5-year relative survival was estimated by period analysis and stratified by sex, age at diagnosis, and region. The 5-year RS of thyroid cancer patients during 2019-2023 was also predicted using the model-based period analysis.
During 2014-2018, the overall 5-year relative survival of thyroid cancer patients was 87.7%, 91.2% for women and 79.4% for men. The 5-year RS decreased along with increasing age at diagnosis, decreasing from 94.9% for age <45 years to 81.3% for age >74 years, while 5-year RS was higher in urban areas than in rural areas (93.2% vs. 86.1%). The 5-year RS for thyroid cancer patients improved greatly between 2004-2008 to 2014-2018. The predicted overall 5-year RS could reach 91.4% over the upcoming 2019-2023 period.
We provided, for the first time in China using period analysis, the most up-to-date 5-year RS for thyroid cancer patients from Taizhou, eastern China, which has important implications for timely evaluation on early detection and screening programs for patients with thyroid cancer in eastern China.
及时评估甲状腺癌患者的长期生存情况对于评估甲状腺癌的早期检测和筛查计划至关重要，但中国此类数据严重缺乏。本研究旨在及时、准确地评估中国东部地区甲状腺癌患者的长期生存情况。
纳入 2004 年至 2018 年期间来自中国东部泰州的四个癌症登记处的甲状腺癌患者。通过时期分析并按性别、诊断时年龄和地区分层来估计 5 年相对生存率。还使用基于模型的时期分析预测 2019 年至 2023 年期间甲状腺癌患者的 5 年 RS。
2014 年至 2018 年期间，甲状腺癌患者的总体 5 年相对生存率为 87.7%，女性为 91.2%，男性为 79.4%。5 年 RS 随诊断时年龄的增加而降低，从<45 岁年龄组的 94.9%下降至>74 岁年龄组的 81.3%，而城市地区的 5 年 RS 高于农村地区（93.2%比 86.1%）。2004 年至 2008 年至 2014 年至 2018 年期间，甲状腺癌患者的 5 年 RS 有了很大的提高。预计在即将到来的 2019 年至 2023 年期间，总体 5 年 RS 可达到 91.4%。
本研究首次使用时期分析方法，为中国东部地区泰州的甲状腺癌患者提供了最新的 5 年 RS，这对于及时评估中国东部地区甲状腺癌患者的早期检测和筛查计划具有重要意义。
